Database of adverse events associated with drugs and drug combinations

被引:18
作者
Poleksic, Aleksandar [1 ]
Xie, Lei [2 ,3 ]
机构
[1] Univ Northern Iowa, Dept Comp Sci, Cedar Falls, IA 50614 USA
[2] CUNY Hunter Coll, Dept Comp Sci, New York, NY 10065 USA
[3] CUNY, Grad Ctr, PhD Comp Sci Program, New York, NY 10065 USA
关键词
TRANSPLANT RECIPIENT; CYCLOSPORINE; BOSENTAN; SAFETY; ETOPOSIDE; SIROLIMUS; WARFARIN;
D O I
10.1038/s41598-019-56525-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Due to the aging world population and increasing trend in clinical practice to treat patients with multiple drugs, adverse events (AEs) are becoming a major challenge in drug discovery and public health. In particular, identifying AEs caused by drug combinations remains a challenging task. Clinical trials typically focus on individual drugs rather than drug combinations and animal models are unreliable. An added difficulty is the combinatorial explosion in the number of possible combinations that can be made using the increasingly large set of FDA approved chemicals. We present a statistical and computational technique for identifying AEs caused by two-drug combinations. Taking advantage of the large and increasing data deposited in FDA's postmarketing reports, we demonstrate that the task of predicting AEs for 2-drug combinations is amenable to the Likelihood Ratio Test (LRT). Our pAERS database constructed with LRT contains almost 77 thousand associations between pairs of drugs and corresponding AEs caused solely by drug-drug interactions (DDIs). The DDIs stored in pAERS complement the existing data sets. Due to our stringent statistical test, we expect many of the associations in pAERS to be unrecorded or poorly documented in the literature.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Association between Polypharmacy and Adverse Events in Patients with Alzheimer's Disease: An Analysis of the Japanese Adverse Drug Event Report Database (JADER)
    Otani, Nobuhiro
    Kanda, Kanae
    Ngatu, Nlandu Roger
    Murakami, Akitsu
    Yamadori, Yusuke
    Hirao, Tomohiro
    MEDICINA-LITHUANIA, 2024, 60 (10):
  • [42] Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review
    Salloum, Antoine
    Habre, Maya
    Chebl, Joanna Abi
    Chebl, Karen Abi
    Atallah, Carl
    Medawar, Georgio
    Kourie, Hampig R.
    IMMUNOTHERAPY, 2022, 14 (06) : 489 - 503
  • [43] Gender differences in the adverse events associated with cardiovascular drugs in a spontaneous reporting system in South Korea
    Han-Heui Park
    Ju Hwan Kim
    Dongwon Yoon
    Hyesung Lee
    Ju-Young Shin
    International Journal of Clinical Pharmacy, 2021, 43 : 1036 - 1044
  • [44] Gender differences in the adverse events associated with cardiovascular drugs in a spontaneous reporting system in South Korea
    Park, Han-Heui
    Kim, Ju Hwan
    Yoon, Dongwon
    Lee, Hyesung
    Shin, Ju-Young
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2021, 43 (04) : 1036 - 1044
  • [45] Treatment-related adverse events associated with antibody drug conjugate in breast cancer
    Collineau, Berenice
    Goncalves, Anthony
    Bertucci, Francois
    de Nonneville, Alexandre
    BULLETIN DU CANCER, 2024, 111 (7-8) : 765 - 781
  • [46] Adverse events associated with mTOR inhibitors
    Pallet, Nicolas
    Legendre, Christophe
    EXPERT OPINION ON DRUG SAFETY, 2013, 12 (02) : 177 - 186
  • [47] Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis
    Chen, Heng
    He, Gefei
    Huang, Juanjuan
    Hu, Lin
    Ma, Junlong
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [48] Abrocitinib-associated adverse events: a real-world pharmacovigilance study using the FAERS database
    Sun, Yu
    Xu, Tao
    Zhu, Suyan
    Xu, Hongbin
    EXPERT OPINION ON DRUG SAFETY, 2025, 24 (02) : 233 - 239
  • [49] Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
    Hoisnard, Lea
    Lebrun-Vignes, Benedicte
    Maury, Sebastien
    Mahevas, Matthieu
    El Karoui, Khalil
    Roy, Lydia
    Zarour, Anissa
    Michel, Marc
    Cohen, Jose L.
    Amiot, Aurelien
    Claudepierre, Pascal
    Wolkenstein, Pierre
    Grimbert, Philippe
    Sbidian, Emilie
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [50] A Survey of the FDA's AERS Database Regarding Muscle and Tendon Adverse Events Linked to the Statin Drug Class
    Hoffman, Keith B.
    Kraus, Christina
    Dimbil, Mo
    Golomb, Beatrice A.
    PLOS ONE, 2012, 7 (08):